Abstract #0136

Can anti-VEGF Antibody Reverse Radiation Necrosis? A Preclinical Investigation

Chong Duan¹, Carlos J Perez-Torres², Liya Yuan³, John A Engelbach⁴, Christina T Tsien⁵, Keith M Rich^3,5, Robert E Schmidt⁶, Joseph JH Ackerman^1,4,7,8, and Joel R Garbow^4,8

¹Chemistry, Washington University in St. Louis, St. Louis, MO, United States, ²Radiological Health Sciences, Purdue University, West Lafayette, IN, United States, ³Neurosurgery, Washington University in St. Louis, St. Louis, MO, United States, ⁴Radiology, Washington University in St. Louis, St. Louis, MO, United States, ⁵Radiation Oncology, Washington University in St. Louis, St. Louis, MO, United States, ⁶Neuropathology, Washington University in St. Louis, St. Louis, MO, United States, ⁷Medicine, Washington University in St. Louis, St. Louis, MO, United States, ⁸Alvin J Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, United States

Recently, radiation necrosis (RN) has been treated clinically using bevacizumab, an anti-VEGF antibody. While bevacizumab reduces radiographic RN volume, the treatment has potentially serious complications and rebound phenomena after the discontinuation of the therapy. In the present study, we investigated the anti-VEGF treatment of pure radiation necrosis in a mouse model. Favorable radiographic appearance of RN were observed following the anti-VEGF treatment. However, the lesions were not completely resolved histologically (e.g., focal mineral deposits were observed in the treated mice). In addition, despite the treatment, VEGF and HIF-1α were still upregulated, which presents the potential risk of recurrence of RN.

This abstract and the presentation materials are available to members only; a login is required.

Join Here